These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7007613)

  • 1. Therapy for urolithiasis by hydroxamic acids. II. Urease inhibitory potency and urinary excretion rate of hippurohydroxamic acid derivatives.
    Kobashi K; Munakata K; Takebe S; Hase J
    J Pharmacobiodyn; 1980 Sep; 3(9):444-50. PubMed ID: 7007613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy for urolithiasis by hydroxamic acids. III. Urease inhibitory potency and urinary excretion rate of N-acylglycinohydroxamic acids.
    Munakata K; Kobashi K; Takebe S; Hase J
    J Pharmacobiodyn; 1980 Sep; 3(9):451-6. PubMed ID: 7007614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of urease activity by dipeptidyl hydroxamic acids.
    Odake S; Nakahashi K; Morikawa T; Takebe S; Kobashi K
    Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2764-8. PubMed ID: 1464106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for urolithiasis with hydroxamic acids. IV. Prevention of infected urinary stone formation with N-(pivaloyl)glycinohydroxamic acid.
    Satoh M; Munakata K; Kitoh K; Seto N; Kanazawa T; Takeuchi H; Yoshida O
    J Pharmacobiodyn; 1981 Jul; 4(7):469-74. PubMed ID: 7028944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of infected urinary stones in rats by urease inhibitor: a new hydroxamic acid derivative.
    Takeuchi H; Kobashi K; Yoshida O
    Invest Urol; 1980 Sep; 18(2):102-5. PubMed ID: 6997228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of infected urinary stones in rats by a new hydroxamic acid, "N-(pivaloyl)glycinohydroxamic acid.
    Takeuchi H; Okada Y; Kobashi K; Yoshida O
    Urol Res; 1982; 10(4):217-9. PubMed ID: 6758273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benurestat, a urease inhibitor for the therapy of infected ureolysis.
    Andersen JA
    Invest Urol; 1975 Mar; 12(5):381-6. PubMed ID: 1089613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S.E.M. study of urease-induced crystalluria in the presence of hydroxamic derivatives.
    Ben Amar M; L'Espérance G; Tawashi R
    Int Urol Nephrol; 1986; 18(3):227-33. PubMed ID: 3771124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of urease activity by hydroxamic acid derivatives of amino acids.
    Kobashi K; Takebe S; Terashima N; Hase J
    J Biochem; 1975 Apr; 77(4):837-43. PubMed ID: 238968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of bacterial urease.
    Griffith DP; Musher DM; Campbell JW
    Invest Urol; 1973 Nov; 11(3):234-8. PubMed ID: 4201416
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prevention of infected urinary stones by urease inhibitor. IV. Treatment of infection stones in rats by a new hydroxamic acid and cefalexin].
    Takeuchi H; Tomoyoshi T; Okada Y; Yoshida O; Kobashi K
    Hinyokika Kiyo; 1983 Mar; 29(3):297-302. PubMed ID: 6375315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, molecular docking, anti-Proteus mirabilis and urease inhibition of new fluoroquinolone carboxylic acid derivatives.
    Abdullah MA; Abuo-Rahma GE; Abdelhafez EM; Hassan HA; Abd El-Baky RM
    Bioorg Chem; 2017 Feb; 70():1-11. PubMed ID: 27908539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of beta-glucosyl-phenolic hydroxamic acids against urease in the presence of microfloral beta-glucosidase.
    Park JB; Imamura L; Kobashi K; Itoh H; Miyazaki T; Horisaki T
    Biol Pharm Bull; 1995 Feb; 18(2):208-13. PubMed ID: 7742785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of infected urinary stones by urease inhibition.
    Griffith DP; Musher DM
    Invest Urol; 1973 Nov; 11(3):228-33. PubMed ID: 4584162
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of effects of novel urease inhibitor, N-(pivaloyl)glycinohydroxamic acid on the formation of an infection bladder stone using a newly designed urolithiasis model in rats.
    Satoh M; Munakata K; Takeuchi H; Yoshida O; Takebe S; Kobashi K
    Chem Pharm Bull (Tokyo); 1991 Apr; 39(4):894-6. PubMed ID: 1893494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of urease as chemotherapeutic agents.
    Rosenstein IJ; Hamilton-Miller JM
    Crit Rev Microbiol; 1984; 11(1):1-12. PubMed ID: 6373150
    [No Abstract]   [Full Text] [Related]  

  • 17. Computerized in vivo research from the growth of urease-producing bacteria in the presence of antibiotics combined with propionhydroxamic acid.
    Rizzo M; Nicoletti P; Bartoletti R; Luciani E
    Contrib Nephrol; 1987; 58():219-21. PubMed ID: 3319403
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of Helicobacter pylori urease activity by hydroxamic acid derivatives.
    Odake S; Morikawa T; Tsuchiya M; Imamura L; Kobashi K
    Biol Pharm Bull; 1994 Oct; 17(10):1329-32. PubMed ID: 7874052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acetylhydroxamic acid in the treatment of nephrolithiasis, caused by infection with urease forming microorganisms].
    Lorenz J; Lorenz K; Dabrowska B; Kowal R
    Z Urol Nephrol; 1989 Dec; 82(12):685-9. PubMed ID: 2698024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of crystallization caused by Proteus mirabilis during the development of infectious urolithiasis by various phenolic substances.
    Torzewska A; Rozalski A
    Microbiol Res; 2014; 169(7-8):579-84. PubMed ID: 24239192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.